Low Serum Vitamin D Levels May Contribute to Gastric Dysmotility in de novo Parkinson's Disease

2016 ◽  
Vol 16 (3-4) ◽  
pp. 199-205 ◽  
Author(s):  
Ki Young Kwon ◽  
Kwang Deog Jo ◽  
Moon Kyu Lee ◽  
Minyoung Oh ◽  
Eyu Nyong Kim ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
De Novo ◽  
Serum Vitamin ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Low Serum

scholarly journals Role of Vitamin D in Parkinson’s Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Khanh Lương ◽  
Lan Nguyễn
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Mhc Class Ii ◽  
Serum Vitamin ◽  
Renin Angiotensin System ◽  
Vitamin D Supplementation ◽  
Heme Oxygenase 1 ◽  
Serum Vitamin D ◽  
Vitamin D Levels

Parkinson’s disease (PD) is the second most common form of neurodegeneration in the elderly population. Clinically, it is characterized by tremor, rigidity, slowness of movement, and postural imbalance. A significant association between low serum vitamin D and PD has been demonstrated, suggesting that elevated vitamin D levels might provide protection against PD. Genetic studies have helped identify a number of proteins linking vitamin D to PD pathology, including the major histocompatibility complex (MHC) class II, the vitamin D receptor (VDR), cytochrome P450 2D6 (CYP2D6), chromosome 22, the renin-angiotensin system (RAS), heme oxygenase-1 (HO-1), poly(ADP-ribose) polymerase-1 gene (PARP-1), neurotrophic factor (NTF), and Sp1 transcription factor. Vitamin D has also been implicated in PD through its effects on L-type voltage-sensitive calcium channels (L-VSCC), nerve growth factor (NGF), matrix metalloproteinases (MMPs), prostaglandins (PGs) and cyclooxygenase-2 (COX-2), reactive oxygen species (ROS), and nitric oxide synthase (NOS). A growing body of evidence suggests that vitamin D supplementation may be beneficial for PD patients. Among the different forms of vitamin D, calcitriol (1,25-dihydroxyvitamin D3) is best indicated for PD, because it is a highly active vitamin D3 metabolite with an appropriate receptor in the central nervous system (CNS).

scholarly journals Effects of vitamin D on motor symptoms and cognitive functions in people with Parkinson’s disease

2021 ◽  
Vol 15 (1) ◽  
pp. 135-140
Author(s):  
Gülbün Asuman Yüksel ◽  
Gizem Gürsoy
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Serum Vitamin ◽  
Control Group ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Significant Difference ◽  
The Relationship ◽  
Lower Vitamin

Aim of the study: Parkinson’s disease is the second most common neurodegenerative disorder. The present study investigates the role of vitamin D deficiency thought to be one of the etiopathological and modifying factors in Parkinson’s disease that is known to be multifactorial. Materials and Methods: Designed as a retrospective review of medical records, this study compares the serum vitamin D levels of the idiopathic Parkinson’s disease patients with and without dementia to those of the healthy individuals with no metabolic/degenerative disorders. It also investigates the relationship between the patients’ Standardized Mini-Mental State Examination (SMMSE) and the Unified Parkinson’s Disease Rating Scale (UPDRS) scores and serum vitamin D levels to show the effects of vitamin D on motor symptoms and cognitive functions. Results: In this study, we compared the serum vitamin D levels of 40 Parkinson’s disease patients and 15 Parkinson’s disease patients with dementia to those of the control group comprising 30 healthy individuals. Vitamin D levels were 21,4±15,9 ng/mL in the control group; 16,5±6,4 ng/mL in Parkinson’s disease patients and 13,8±4,5 ng/mL in Parkinson’s disease patients with dementia. All the patient groups had significantly lower vitamin D levels than the control group (p<0,005). Within the Parkinson’s disease group, furthermore, the dementia group had lower vitamin D levels than the non-dementia group. Having examined the relationship between the SMMSE scores and serum vitamin D levels, we found a significant difference in the Parkinson’s disease dementia group (p: 0,020), as well as a relationship of 59,4% in the same direction. On the other hand, there was no significant difference in either patient group in the scores of UPDRS evaluating clinical disability. Conclusion: Consistent with the literature, the present study found that people with Parkinson’s disease had lower mean values of serum vitamin D levels than the control group and showed that serum vitamin D levels were correlated with the cognitive performance. However, the study could not find a relationship between the serum vitamin D levels and the motor performance.

Bone mineral density and serum vitamin D status in Parkinson's disease: Are the stage and clinical features of the disease important?

2020 ◽  
Vol 68 (2) ◽  
pp. 394 ◽  
Author(s):  
ErhanArif Ozturk ◽  
Ibrahim Gundogdu ◽  
Burak Tonuk ◽  
Ebru Umay ◽  
BilgeGonenli Kocer ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Clinical Features ◽  
Bone Mineral ◽  
Serum Vitamin ◽  
Vitamin D Status ◽  
Mineral Density ◽  
Serum Vitamin D

scholarly journals Low Serum Vitamin D is Independently Associated with Acute Ischemic Stroke

2018 ◽  
Vol 30 (1) ◽  
pp. 34-37
Author(s):  
Md Mahabubul Islam Majumder ◽  
Md Nazmul Hasan Chowdhury ◽  
Ashiqur Rahman Khan ◽  
Tarek Ahmed ◽  
Saleh Ahmed
Keyword(s):  
Vitamin D ◽  
Ischemic Stroke ◽  
Acute Stroke ◽  
Acute Ischemic Stroke ◽  
Serum Vitamin ◽  
Multivariate Logistic Regression Analysis ◽  
Vitamin D Status ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Low Serum

Low serum vitamin D levels have been associated with various vascular diseases. Very little is known its association with acute stroke in Bangladeshi population. We therefore sought to assess whether low serum 25- hydroxyvitamin D, a marker of vitamin D status is associated with acute stroke. We performed a prospective study in Comilla Medical Collage, Comilla, from November 2016 to November 2017. All the patients diagnosed as acute ischemic stroke on the basis of CT scan or MRI of brain. Patients were eligible for inclusion if they were admitted with onset of symptoms within 24 hours. Estimation of 25(OH)D level was done at presentation. The patients were stratified by vitamin D status, >30 as vitamin D sufficient, vitamin D 20-20.9 as insufficient and finally vitamin D<20 as deficient. Multivariate logistic regression analysis revealed that out of the desired 7 variables, smoking, hypertension and low serum vitamin D were found independent predictors for acute stroke with ORs being 1.44, 4.23 and 2.39 respectively. Vitamin D deficiency represents an important risk factor for acute stroke and it might play a causal role in the development adverse events associated with stroke.Medicine Today 2018 Vol.30(1): 34-37

scholarly journals A170 VITAMIN D IN IBD PATIENTS – A RETROSPECTIVE REVIEW

2020 ◽  
Vol 3 (Supplement_1) ◽  
pp. 35-36
Author(s):  
R A MacMillan ◽  
T Ponich
Keyword(s):  
Vitamin D ◽  
Bone Density ◽  
Disease Severity ◽  
Regression Coefficient ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Serum Vitamin D ◽  
Mayo Score ◽  
Vitamin D Levels ◽  
Low Serum

Abstract Background Vitamin D is a critical factor in bone remodelling, calcium absorption and may promote anti-inflammatory cytokines in the gut. Inflammatory bowel disease (IBD) is associated with a reduction in serum Vitamin D levels and a chronic inflammatory state, both of which are strong risk factors for bone density loss affecting IBD patients. Despite European and North American IBD maintenance guidelines for Vitamin D monitoring and bone density scans, there are limited North American investigations into factors influencing serum Vitamin D levels in the IBD patient population specifically. Aims We investigated whether patient demographics, disease severity indexes and/or inflammatory markers were linked to low serum Vitamin D levels in our IBD patients. We also established the extent of Vitamin D serum deficiencies and supplementation rates in our IBD patients. Methods A retrospective chart review of a single clinician’s practice at London Health Science Centre, Victoria Hospital, over the past 20 months, was performed to: 1) assess the frequency of low serum 25-OH Vitamin D (25-OH D) in the IBD patient population and 2) determine whether patient disease severity was linked to lower 25-OH D levels. A multivariate regression analysis was performed assessing Crohn’s Disease (CD) or Ulcerative Colitis (UC) patient factors: age, sex, disease duration, seasonality, current pharmacologic treatments, past surgeries, CD Activity Index, UC Mayo score, C-reactive protein, and fecal calprotectin (Fcal) level. Results 175 IBD patients had at least one 25-OH D measurement with 71 patients actively on Vitamin D therapy. Of UC and CD patients who were not on Vitamin D therapy, 63% (17/27) and 79% (61/77) were 25-OH D deficient, respectively. 25-OH D levels in the CD population was associated with Vitamin D supplementation (regression coefficient [RC] 23.99, 95% confidence interval [CI] 14.54 to 33.45), summer season ([RC] 9.90, [CI] 0.56 to 19.24), and past bowel resection ([RC] -10.61, [CI] -20.48 to -0.76). 25-OH D levels in the UC population was associated with Vitamin D supplementation (regression coefficient [RC] 47.23, 95% confidence interval [CI] 27.62 to 66.83), and Mayo severity scores ([RC] -23.01, [CI] -41.82 to -4.20). Fcal (78 patients) was inversely associated with 25-OH D levels but the trend was not significant. Conclusions Overall, 25-OH D levels were lower in both the UC and CD patient populations relative to the already deficient Canadian population. However, IBD patients are responsive to Vitamin D supplementation. Tools with more objective evidence of disease severity such as UC Mayo score and fcal should be prioritized for identifying the IBD population requiring supplementation. Funding Agencies None

Decreased Neuromuscular Function in Crohn’s Disease Patients Is Not Associated with Low Serum Vitamin D Levels

2012 ◽  
Vol 58 (2) ◽  
pp. 526-533 ◽  
Author(s):  
Amanda J. Salacinski ◽  
Miguel D. Regueiro ◽  
Craig E. Broeder ◽  
Jean L. McCrory
Keyword(s):  
Vitamin D ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Serum Vitamin ◽  
Neuromuscular Function ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Low Serum

Variations in serum vitamin D status during cancer chemotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19550-e19550
Author(s):  
Bogda Koczwara ◽  
Richard John Woodman ◽  
Laisa Vicki Teleni ◽  
Michael Kimlin ◽  
Euan Thomas Walpole ◽  
...  
Keyword(s):  
Vitamin D ◽  
Demographic Data ◽  
Serum Vitamin ◽  
Sun Exposure ◽  
Unknown Primary ◽  
Curative Intent ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
The Impact ◽  
Low Serum

e19550 Background: Low serum vitamin D in cancer patients has been associated with inferior cancer outcomes and bone loss. The impact of chemotherapy on vitamin D levels is not known. We examined serum vitamin D levels during chemotherapy to identify magnitude and predictors of change. Methods: A prospective study of chemotherapy naïve patients commencing chemotherapy in two different sun exposure areas. Vitamin D (25(OH)D) deficiency was defined as ≤25 nmol/L and insufficiency 26-50 nmol/L. Demographic data, nutrition, sun exposure, season and biochemical parameters were collected at baseline 6 weeks (6W) and 12 weeks (12W) since commencement of treatment. The effects were assessed using a multivariate multilevel linear regression model that also included age, gender and BMI. Results: 82 Caucasian and 3 indigenous patients were enrolled. Median age was 57 (21-85) years. Forty-nine (58%) were female; 54 (65%) were treated with curative intent. Tumours included 29 (34%) breast,12 (14%) colorectal, 9 (11%) lymphomas, 7 (8%) leukemias, 7 (8%) lung, 5 (6%) ovarian, 3 (4%) testis, 3 (4%) unknown primary and 10 (11%) others. Median weight was 75 kg (50-151) and median BMI was 26.9 kg/m2 (17.7- 44.5). Seventy-six (89%) and 55 (65%) patients were receiving chemotherapy treatment at 6W and 12W respectively. Mean (±SD) serum 25(OH)D at baseline was 49.2±22.3 nmol/L. Ten (12%) patients were vitamin D deficient at baseline and a further 33 (41%) had insufficient levels. Mean serum 25(OH)D status was higher in higher sun exposure locations (61.9±22.1 nmol/L vs 42.2±19.2 nmol/L, p<0.001), varied according to season (spring=46.9±20.3 nmol/L, summer=50.8±18.2 nmol/L, fall=76.4±25.2 nmol/L, winter=36.5±15.7 nmol/L, p<0.001) and changed with treatment period (baseline=49.2±22.3 nmol/L, 6W=40.9±19.0 nmol/L, 12W=45.9±19.7 nmol/L, p=0.002). There was no association between 25(OH)D status and age, gender, BMI or nutritional status. Conclusions: Chemotherapy is associated with a fall in serum 25(OH)D. Further research is needed to determine the underlying mechanism, the impact of low serum 25(OH)D on patient outcomes and the potential role for screening and vitamin D supplementation in this group.

scholarly journals Gastric Dysmotility and Low Serum Vitamin D Levels in Patients with Gastroparesis

2013 ◽  
Vol 45 (03) ◽  
pp. 254-254 ◽  
Author(s):  
A. Kedar ◽  
Y. Nikitina ◽  
O. Henry ◽  
K. Abell ◽  
V. Vedanarayanan ◽  
...  
Keyword(s):  
Vitamin D ◽  
Serum Vitamin ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Low Serum
Sign in / Sign up

Export Citation Format

Share Document